Michael Riskin

“Maybe first I'll ask on mineral nutrition. That's done better the last couple quarters. I mean, I know you guys always talk about that being a pretty much pass-through business.”

“I want to ask about some of the other actions you're taking. We've seen through some of our channel checks some pretty aggressive job cut announcements. You've talked about cost controls.”

“I want to go back to Chromium and the single cell platform. You know, Chromium consumables are kind of flat, effectively quarter over quarter, just sequentially start the year.”

“And congrats on the quarter and strong result. I'll stick with Zanrelli and Quattro specifically. You know, you've really continued to talk up share gains, share gains, share gains in terms of clinic penetration, in terms of market share, you know, both for Zanrelli, you know, year over year, quarter over quarter.”

“Bergen, maybe kind of going back to some of your prepared remarks on DSA strength, you know, the book-to-build commentary. You talked about demand trends, both in biotech and pharma.”